Is Accelerated Aging Tied to Early-Onset Carcinogenesis? - Scorecard - MDSpire
Advertisement
Is Accelerated Aging Tied to Early-Onset Carcinogenesis?
Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.
Clinical Scorecard: Is Accelerated Aging Tied to Early-Onset Carcinogenesis?
At a Glance
Category
Detail
Condition
Early-Onset Cancers
Key Mechanisms
Biological aging assessed through blood-based measures such as PhenoAge, KDM, and metabolomic aging scores.
Target Population
Patients younger than 55 years.
Care Setting
Observational study using data from UK Biobank and All of Us Research Program.
Key Highlights
Patients born between 1965 and 1974 had a 23% higher PhenoAge-defined age gap compared to those born between 1950 and 1954.
Each 1-standard deviation increase in PhenoAge-defined age gap was associated with an 8% higher likelihood of early-onset solid cancer.
Strongest associations observed for lung, gastrointestinal, and endometrial cancers.
Organ-specific aging linked to early-onset cancers, with immune-system aging associated with lung cancer and adipose-tissue aging with colorectal cancer.
Accelerated biological aging may reflect cumulative effects of multiple exposures and physiologic changes.
Guideline-Based Recommendations
Diagnosis
Monitor biological aging using PhenoAge and other blood-based measures.
Management
Consider organ-specific aging factors in early-onset cancer risk assessments.
Monitoring & Follow-up
Track biological age gaps across different birth cohorts.
Risks
Increased risk of early-onset solid cancers associated with greater biological aging.
Patient & Prescribing Data
Patients younger than 55 years with potential early-onset cancers.
Biological aging may serve as an integrative measure for studying early-onset cancer risk factors.
Clinical Best Practices
Utilize multiple aging measures for comprehensive risk assessment.
Conduct further studies to validate organ-specific aging findings.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
